Download PDF
Thromb Haemost 1996; 76(05): 761-767
DOI: 10.1055/s-0038-1650657
Original Article
Schattauer GmbH Stuttgart

Decreased Expression of PAI-2 mRNA and Protein in Pregnancies Complicated with Intrauterine Fetal Growth Retardation

Salvador Grancha
1   The Research Center, La Fe Universitary Hospital, Valencia, Spain
,
Amparo Estellés
1   The Research Center, La Fe Universitary Hospital, Valencia, Spain
,
Juan Gilabert
2   Maternal Center, La Fe Universitary Hospital, Valencia, Spain
,
Melitina Chirivella
3   Department of Pathology, La Fe Universitary Hospital, Valencia, Spain
,
Francisco España
1   The Research Center, La Fe Universitary Hospital, Valencia, Spain
,
Justo Aznar
4   Clinical Pathology, La Fe Universitary Hospital, Valencia, Spain
› Author Affiliations
Further Information

Publication History

Received 03 April 1996

Accepted after revision 21 June 1996

Publication Date:
11 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

An increase in plasma plasminogen activator inhibitors (PAIs), fundamentally PAI type 2 (PAI-2), has been described in normal pregnancy probably because the placenta is the main source of the high plasma levels of this protein. Although we have previously described plasmatic alterations of these inhibitors in pregnancies complicated with intrauterine fetal growth retardation (IUGR), no reports have been published about placental PAI-2 mRNA expression. In the present study, the placental PAI-2 expression determined in pregnancies complicated with IUGR and in severe preeclamptic patients was compared with that of normal pregnancies in order to identify the placental cell types expressing PAI-2 and to determine whether the production of PAI-2 is altered in placentas from IUGR. In situ hybridization analyses show that the syncytiotrophoblasts are the cells with the greatest PAI-2 expression in placenta. We report that the significant decrease in plasma and placental PAI-2 levels in IUGR groups is fundamentally due to a diminished expression of PAI-2 mRNA in placenta.

 

  • References

  • 1 Kliman HJ, Contifaris C, Feinberg RF, Strauss III JF. Implantation: In Vitro Models Utilizing Human Tissues. In: Implantation Yoshinaga K. ed. Adams Blastocyst Publishing Group Ltd; Boston: 1989: 83-91
  • 2 Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemostas Thromb 1988; 9: 87-115
    PubMedGoogle Scholar
  • 3 Ny T, Leonardsson G, Peng XR, Hagglund AC, Ny A, Liu K. Role of Plasminogen Activators and Their Inhibitors in Ovulation and Reproduction. In: Fibrinolytic inhibitors. Cellular, biological and clinical aspects Aznar J, Gilabert J, Estellés A. eds Garsi-Masson; Spain: 1994: 32-42
  • 4 Gilabert J, Estellés A, Grancha S, España F, Aznar J. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in preeclampsia. Human Reproduction 1995; 10: 121-131
    CrossrefPubMedGoogle Scholar
  • 5 Kruithof EKO. Plasminogen activator inhibitor type 1. Biochemical, biological and clinical aspects. Fibrinolysis 1988; 2: 59-70
    PubMedGoogle Scholar
  • 1 Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis 1991; 5: 197-206
    PubMedGoogle Scholar
  • 7 Astedt B, Lecander I, Ny T. The placental type plasminogen activator inhibitor, PAI-2. Fibrinolysis 1987; 1: 281-285
    PubMedGoogle Scholar
  • 8 Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-4024
    PubMedGoogle Scholar
  • 9 Bachmann F. The enigma PAI-2. Gene expression, evolutionary and functional aspects. Thromb Haemost 1995; 74: 172-179
    PubMedGoogle Scholar
  • 10 Kawano T, Morimoto K, Uemura Y. Partial purification and properties of urokinase inhibitor from human placenta. J Biochem 1970; 67: 333-342
    CrossrefPubMedGoogle Scholar
  • 11 Philips M, Juul AG, Thorsen S, Selmer J, Zeuthen J. Immunological relationships between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta. Thromb Haemost 1986; 55: 213-217
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Estellés A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S, España F, Loskutoff DJ, Schleef RR. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. Blood 1994; 84: 143-150
    CrossrefPubMedGoogle Scholar
  • 13 Dear AE, Medcalf RL. The cellular and molecular biology of plasminogen activator inhibitor type-2. Fibrinolysis 1995; 9: 321-330
    PubMedGoogle Scholar
  • 14 Hathaway W, Bonnar J. Hemostatic Alterations in Hypertensive and Placental Insufficiency Disorders of Pregnancy. In: Hemostatic Disorders of the Pregnant Woman and Newborn Infant Hathaway W, Bonnar J. eds John Wiley & Sons; New York: 1987: 185-201
  • 15 Cunninghan FG, MacDonald PC, Gant NF. In: Williams’ Obstetrics, Eighteenth Edition. Appleton & Lange Connecticut/San Mateo; CA, Norwalk: 1987
  • 16 Kruithof EKO, Tran-Thang C, Gudinchet A, Havert J, Nicoloso G, Genton C, Welti H, Bachmann F. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors. Blood 1987; 69: 460-466
    PubMedGoogle Scholar
  • 17 Estellés A, Gilabert J, Aznar J, Loskutoff DJ, Schleef RR. Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 1989; 74: 1332-1338
    PubMedGoogle Scholar
  • 18 Estellés A, Gilabert J, Andrés C, España F, Aznar J. Plasminogen activator inhibitor type 1 and plasminogen activators in amniotic fluid during pregnancy. Thromb Haemost 1990; 64: 281-285
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Lindoff C, Lecander I, Astedt B. Fibrinolytic components in individual consecutive plasma samples during normal pregnancy. Fibrinolysis 1993; 7: 190-194
    PubMedGoogle Scholar
  • 20 Aznar J, Gilabert J, Estellés A, España F. Fibrinolytic activity and protein C in preeclampsia. Thromb Haemost 1986; 55: 314-317
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Gilabert J, Estellés A, Aznar J, España F, Andrés C, Santos T, Valles J. Contribution of platelets to increased plasminogen activator inhibitor type 1 in severe preeclampsia. Thromb Haemost 1990; 63: 361-366
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Estellés A, Gilabert J, España F, Aznar J, Galbis M. Fibrinolytic parameters in normotensive pregnancy with intrauterine fetal growth retardation and in severe preeclampsia. Am J Obstet Gynecol 1991; 165: 138-142
    CrossrefPubMedGoogle Scholar
  • 23 Ballegeer V, Spitz B, Kieckens L, Moreau H, Van Assche A, Collen D. Predictive value of increased plasma levels fibronectine in gestational hypertension. Am J Obstet Gynecol 1989; 161: 432-436
    CrossrefPubMedGoogle Scholar
  • 24 de Boer K, Lecander J, ten Cate JW, Bom JJJ, Treffers PE. Placental type plasminogen activator inhibitor in preeclampsia. Am J Obstet Gynecol 1988; 158: 518-522
    CrossrefPubMedGoogle Scholar
  • 25 Koh SCL, Anandakumar C, Montan S, Ratnam SS. Plasminogen activators, plasminogen activator inhibitors and markers of intravascular coagulation in pre-eclampsia. Gynecol Obstet Invest 1993; 35: 214-221
    CrossrefPubMedGoogle Scholar
  • 26 Reith A, Booth NA, Moore NR, Cruickshank DJ, Bennett B. Plasminogen activator inhibitors (PAI-1 and PAI-2) in normal pregnancies, preeclampsia and hydatidiform mole. Br J Obstet Gynecol 1993; 100: 370-374
    CrossrefPubMedGoogle Scholar
  • 27 Lindoff C, Astedt B. Plasminogen activator of urokinase type and its inhibitor of placental type in hypertensive pregnancies and in intrauterine growth retardation: possible markers of placental function. Am J Obstet Gynecol 1994; 171: 60-64
    CrossrefPubMedGoogle Scholar
  • 28 Halligan A, Bonnar J, Sheppard B, Darling M, Walshe J. Haemostatic fibrinolytic and endothelial variables in normal pregnancies and preeclampsia. Br J Obstet Gynecol 1994; 101: 488-492
    CrossrefPubMedGoogle Scholar
  • 29 Estellés A, Gilabert J, Aznar J, España F, Schleef RR, Loskutoff DJ. Cellular Expression and Potential Roles of Plasminogen Activator Inhibitors in Normal and Pathological Pregnancies. In: Fibrinolytic inhibitors. Cellular, biological and clinical aspects Aznar J, Gilabert J, Estellés A. eds. Garsi-Masson; Spain: 1994: 43-59
  • 30 Gilabert J, Estellés A, Ayuso MJ, España F, Chirivella M, Grancha S, Mico JM, Aznar J. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation. Gynecol Obstet Invest 1994; 38: 157-162
    CrossrefPubMedGoogle Scholar
  • 31 Feinberg RF, Kao L-C, Haimowitz JE, Queenan Jr JT, Wun T-C, Strauss III JF, Kliman HJ. Plasminogen activator inhibitor types 1 and 2 in human trophoblasts. PAI-1 is an immunocytochemical marker of invading tropho-blasts. Lab Invest 1989; 61: 20-26
    PubMedGoogle Scholar
  • 32 Ott WJ. The diagnosis of altered fetal growth. Obstet Gynecol Clin North Am 1988; 15: 237-262
    PubMedGoogle Scholar
  • 33 Canavagh D, Kmuppel LA. Preeclampsia and Eclampsia. In Principles and Practice of Obstetrics and Perinatology Iffy L, Kaminetzky H. eds John Wiley & Sons; New York: 1981: 1271-1289
  • 35 Grancha S, Estellés A, Gilabert J, España F, Aznar J. PAI-1 and PAI-2 mRNA detection in human placental extracts with digoxigenin-based nonradioactive methods. Rev Iberoamer Tromb Hemostasia 1995; 8: 145-149
    PubMedGoogle Scholar
  • 35 Ye RD, Wun T, Sadler JE. cDNA cloning and expression in Escherichia coli of a plasminogen activator inhibitor from human placenta. J Biol Chem 1987; 262: 3718-3725
    PubMedGoogle Scholar
  • 36 Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol, chloroform extraction. Anal Biochem 1987; 162: 156-159
    PubMedGoogle Scholar
  • 37 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002
    CrossrefPubMedGoogle Scholar
  • 38 Kumar S, Baglioni C. Protection from tumor necrosis factor-mediated cy-tolysis by overexpression of plasminogen activator inhibitor type-2. J Biol Chem 1991; 266: 20960-20964
    PubMedGoogle Scholar
  • 39 Dickinson JL, Bates EJ, Ferrante A, Antalis TM. Plasminogen activator inhibitor type 2 inhibits tumor necrosis factor alfa-induced apoptosis - Evidence for an alternate biological function. J Biol Chem 1995; 270: 27894-27904
    CrossrefPubMedGoogle Scholar
  • 40 von Heijne G, Liljestrom P, Mikus P, Andersson H, Ny T. The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. J Biol Chem 1991; 266: 15240-15243
    PubMedGoogle Scholar